Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 18, 2025 08:30 ET | Source: Alvotech

Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

HYDERABAD, India and REYKJAVIK, Iceland, March 18, 2025 (GLOBE NEWSWIRE) -- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries...
March 18, 2025 08:30 ET | Source: Alvotech

Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as “Dr. Reddy’s”) and Alvotech (NASDAQ: ALVO), a global biotech...
March 18, 2025 08:30 ET | Source: Alvotech

Matvæla- og lyfjaeftirlit Bandaríkjanna (FDA) samþykkir að taka til afgreiðslu umsókn um markaðsleyfi fyrir AVT03, fyrirhugaða hliðstæðu við Prolia og Xgeva

Alvotech (NASDAQ: ALVO) og samstarfsaðili þess, alþjóðlega lyfjafyrirtækið Dr. Reddy‘s Laboratories Ltd. („Dr. Reddy‘s“) tilkynntu í dag að Matvæla- og lyfjaeftirlit Bandaríkjanna (FDA) hafi samþykkt...
March 07, 2025 09:00 ET | Source: Alvotech

Alvotech Meeting Investors and Participates in Fireside Chat At Barclays 27th Global Healthcare Conference in Miami, Florida

REYKJAVIK, Iceland, March 07, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
March 07, 2025 09:00 ET | Source: Alvotech

Alvotech Meeting Investors and Participates in Fireside Chat At Barclays 27th Global Healthcare Conference in Miami, Florida

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in Barclays 27th...
March 07, 2025 09:00 ET | Source: Alvotech

Alvotech fundar með fjárfestum á alþjóða heilbrigðisráðstefnu Barclays fjárfestingabankans í Miami og situr fyrir svörum

Alvotech (NASDAQ: ALVO) tekur þátt í árlegri heilbrigðisráðstefnu fjárfestingabankans Barclays í Miami í Flórida, sem haldin verður í 27. skipti dagana 11. – 13. mars nk. Róbert Wessman,...
February 24, 2025 08:00 ET | Source: Alvotech

Alvotech to Report Full Year Financial Results for 2024 on March 26, 2025, and Hosts Conference Call on March 27, 2025, at 8:00 am ET

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results...
February 24, 2025 08:00 ET | Source: Alvotech

Alvotech heldur kynningarfund fyrir fjárfesta 27. mars 2025, eftir birtingu uppgjörs fyrir árið 2024 og fjórða ársfjórðung

Alvotech (NASDAQ: ALVO) birtir uppgjör fyrir fjórða ársfjórðung 2024 og ársuppgjör 2024 miðvikudaginn 26. mars nk. eftir lokun markaða. Uppgjörsfundur með greinendum, sem sendur er út í beinum...
February 21, 2025 06:00 ET | Source: Alvotech

Alvotech og Teva tilkynna að sala er hafin í Bandaríkjunum á Selarsdi (ustekinumab-aekn), hliðstæðu við líftæknilyfið Stelara

Matvæla- og lyfjastofnun Bandaríkjanna (FDA) hefur heimilað notkun Selarsdi fyrir allar sömu ábendingar og frumlyfsins StelaraFDA hefur jafnframt tilkynnt að öll lyfjaform Selarsdi verði útskiptanleg...
February 21, 2025 06:00 ET | Source: Alvotech

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference product Stelara® (ustekinumab) and has granted a provisional determination of...